LIVANOVA PLC (LIVN) Stock News

USA - Nasdaq - NASDAQ:LIVN - GB00BYMT0J19 - Common Stock

63.68 USD

+0.57 (+0.9%)

Last: 12/2/2025, 8:00:02 PM

63.8 USD

+0.12 (+0.19%)

Pre-Market: 12/3/2025, 7:38:40 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

LIVN Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: LivaNova PLC

LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

8 days ago - By: LivaNova PLC

LivaNova to Present at Piper Sandler Healthcare Conference in December

9 days ago - By: LivaNova PLC

LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services

a month ago - By: Benzinga - Mentions: TECH INSE GEF SKYT ...

Earnings Scheduled For November 5, 2025

4 months ago - By: Benzinga - Mentions: OEC VTLE DIN INSE ...

Earnings Scheduled For August 6, 2025

21 days ago - By: LivaNova PLC

LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day

a month ago - By: Zacks Investment Research - Mentions: STXS

LivaNova (LIVN) Tops Q3 Earnings and Revenue Estimates

a month ago - By: LivaNova PLC

LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance

a month ago - By: Zacks Investment Research

Is LivaNova (LIVN) Stock Undervalued Right Now?

a month ago - By: LivaNova PLC

LivaNova to Present at Wolfe Research Healthcare Conference in November

2 months ago - By: LivaNova PLC

LivaNova to Announce Third-Quarter 2025 Results

2 months ago - By: LivaNova PLC

LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting

2 months ago - By: Zacks Investment Research - Mentions: RMD INSP NYXH

Nyxoah Expands in the Middle East to Provide Wider Access to Genio

2 months ago - By: Zacks Investment Research

Should Value Investors Buy LivaNova (LIVN) Stock?

3 months ago - By: Zacks Investment Research - Mentions: TCMD

LivaNova PLC (LIVN) Soars to 52-Week High, Time to Cash Out?

3 months ago - By: LivaNova PLC

LivaNova Appoints Donald Zurbay as a New Director

3 months ago - By: LivaNova PLC

LivaNova to Host Investor Day on November 12, 2025

3 months ago - By: LivaNova PLC

LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September

4 months ago - By: LivaNova PLC

LivaNova Launches Essenz Perfusion System in China

4 months ago - By: Zacks Investment Research - Mentions: RMD INSP NYXH

Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea

4 months ago - By: Zacks Investment Research - Mentions: GMED

LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates

4 months ago - By: LivaNova PLC

LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance

4 months ago - By: Zacks Investment Research - Mentions: AVNS

Avanos Medical (AVNS) Misses Q2 Earnings Estimates

4 months ago - By: Yahoo Finance

Jefferies Maintained a Buy Rating on LivaNova PLC (LIVN)

4 months ago - By: Yahoo Finance

Jefferies Reaffirms ‘Buy’ Rating on LivaNova PLC (LIVN) with $79 PT

5 months ago - By: Yahoo Finance

Jefferies Reiterates a Buy Rating on LivaNova PLC (LIVN) With a $79 PT

5 months ago - By: LivaNova PLC

LivaNova to Announce Second-Quarter 2025 Results

6 months ago - By: LivaNova PLC

CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

6 months ago - By: LivaNova PLC

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

6 months ago - By: LivaNova PLC

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

7 months ago - By: Yahoo Finance - Mentions: UBS KR HPQ DB ...

MongoDB and Asana downgraded: Wall Street's top analyst calls

7 months ago - By: LivaNova PLC

LivaNova to Present at the Jefferies Global Healthcare Conference

7 months ago - By: LivaNova PLC

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

7 months ago - By: LivaNova PLC

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy